Merck & Co Inc
NYSE: MRK
$102.97
+$1.35 (+1.3%)
Real Time Data Delayed 15 Min.
MRK Articles
As each new year replaces the prior year, 24/7 Wall St. looks at the individual targets on all 30 Dow Jones Industrial Average price targets from Wall Street analysts to come up with a peak price for...
Published:
Last Updated:
The lineup of the Dogs of the Dow, simply the ten highest dividend yield stocks of the thirty Dow Jones Industrial Average components, appears to be undergoing a bit of change for 2012. There is a...
Published:
Last Updated:
We recently gave a full review of the DJIA components we expect to raise their dividend payouts in the weeks and months ahead. Among those we expect to raise the dividend is Pfizer Inc. (NYSE:...
Published:
Last Updated:
AuthorDendreon Corporation (NASDAQ: DNDN) is supposed to be the king of prostate cancer with its PROVENGE treatment. Unfortunately, PROVENGE sales ran slower than expected after the FDA took...
Published:
Last Updated:
Dividends are still rising and equity and income investors should expect more of the same for 2012. The Walt Disney Company (NYSE: DIS) joined in on the dividend hike brigade with another dividend...
Published:
Last Updated:
China’s factory activity reaches a 32-month low. (Reuters) Merck (NYSE: MRK) pays $950 million to settle Vioxx charges brought by the government. (Reuters) FCC head wants more examination of the...
Published:
It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1 billion to fail to get the drug to market. Like the movie business, a drug company tries to develop that...
Published:
The economic choppiness is coming to a head with the age of dividend hikes. The pressure is going to remain for companies to continue returning capital to shareholders while also looking for...
Published:
Last Updated:
Markets opened slightly lower this morning and spent the morning trying to decide on a direction. The Reuters/University of Michigan Consumer Sentiment Index rose more than expected, but even that...
Published:
Last Updated:
Novartis (NYSE: NVS) said it would cut 2,000 workers and outsource some functions to companies that will do the work for less than it can. Novartis will take a restructuring charge of $300 million....
Published:
A company can spend billions of dollars on R&D and get little respect as an innovator. Even though that is the conclusion of a new study by Booz & Co., the conclusion is misleading. Booz...
Published:
Drug maker Eli Lilly & Co. (NYSE: LLY) reported third-quarter earnings this morning, and the company did a little better than analysts expected, but worries persist that the company will be hit...
Published:
Last Updated:
Sales for the big pharmaceutical companies are expected to be hit by pricing pressure in Europe, a lack of urgent new on the coming flu season, lower rates of prescription writing, and more...
Published:
Last Updated:
Angela Merkel faces a test: will her own party support money being used for the bailout of Greece? (Reuters) Bernanke says the Fed may have to act if inflation falls below targets. (Reuters)...
Published: